Antiretroviral drugs for treatment and prevention of HIV infection in Adults: 2016 recommendations of the international antiviral society-USA Panel

JAMA - Journal of the American Medical Association

Volumn 316, Issue 2, 2016, Pages 191-210

  Günthard, Huldrych F ^a   Saag, Michael S ^b   Benson, Constance A ^c   Del Rio, Carlos ^d   Eron, Joseph J ^e   Gallant, Joel E ^f   Hoy, Jennifer F ^g   Mugavero, Michael J ^b   Sax, Paul E ^h   Thompson, Melanie A ⁱ   Gandhi, Rajesh T ^j   Landovitz, Raphael J ^k   Smith, Davey M ^l   Jacobsen, Donna M ^m   Volberding, Paul A ⁿ  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^f Southwest CARE Center   (Argentina)

^g MONASH UNIVERSITY   (Australia)

^h BRIGHAM AND WOMEN S HOSPITAL   (United States)

ⁱ AIDS Research Consortium of Atlanta   (United States)

^j MASSACHUSETTS GENERAL HOSPITAL   (United States)

^k UNIVERSITY OF CALIFORNIA   (United States)

^l UNIVERSITY OF CALIFORNIA   (United States)

^m International Antiviral Society USA   (United States)

ⁿ UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ABACAVIR PLUS DOLUTEGRAVIR PLUS LAMIVUDINE; ABACAVIR PLUS LAMIVUDINE; ANTIRETROVIRUS AGENT; ATAZANAVIR PLUS RITONAVIR; CABOTEGRAVIR; COBICISTAT; COBICISTAT PLUS ELVITEGRAVIR PLUS EMTRICITABINE PLUS TENOFOVIR ALAFENAMIDE; DARUNAVIR PLUS RITONAVIR; DOLUTEGRAVIR; EFAVIRENZ; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ELVITEGRAVIR; EMTRICITABINE; EMTRICITABINE PLUS RILPIVIRINE PLUS TENOFOVIR ALAFENAMIDE; EMTRICITABINE PLUS TENOFOVIR ALAFENAMIDE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ENTECAVIR; HLA B ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTEGRASE INHIBITOR; LAMIVUDINE PLUS LOPINAVIR PLUS RITONAVIR; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RALTEGRAVIR; RIFAPENTINE; TENOFOVIR ALAFENAMIDE; TENOFOVIR DISOPROXIL; UNINDEXED DRUG;

ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL EFFECTIVENESS; DISEASE TRANSMISSION; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; EVIDENCE BASED MEDICINE; FRACTURE; GASTROINTESTINAL DISEASE; HEALTH CARE COST; HEART INFARCTION; HEPATITIS B; HEPATITIS C; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; KIDNEY DISEASE; LATENT TUBERCULOSIS; MEDICAL LITERATURE; MEDICAL RESEARCH; MEDICATION COMPLIANCE; NONHUMAN; OSTEOPOROSIS; PATIENT CARE; PATIENT MONITORING; POST EXPOSURE PROPHYLAXIS; PRE-EXPOSURE PROPHYLAXIS; PREGNANCY; PREVENTIVE MEDICINE; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT PLANNING; TREATMENT RESPONSE; TUBERCULOSIS; VIRUS LOAD; ADOLESCENT; ADULT; AGED; AIDS RELATED COMPLEX; COMBINATION DRUG THERAPY; FEMALE; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; MALE; MIDDLE AGED; PRACTICE GUIDELINE; PROGNOSIS; TREATMENT FAILURE; VIREMIA; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-RETROVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; POST-EXPOSURE PROPHYLAXIS; PRE-EXPOSURE PROPHYLAXIS; PREGNANCY; PROGNOSIS; TREATMENT FAILURE; VIRAL LOAD; VIREMIA; YOUNG ADULT;

EID: 84978371920     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2016.8900     Document Type: Article

References (212)

1. Günthard HF, Aberg JA, Eron JJ, et al.; International Antiviral Society-USA Panel. Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel. JAMA. 2014; 312(4): 410-425.
2. Lundgren JD, Babiker AG, Gordin F, et al.; INSIGHT START Study Group. Initiation of antiretroviral therapy in early asymptomatic HIV Infection. N Engl J Med. 2015; 373(9):795-807.
3. Danel C, Moh R, Gabillard D, et al.; TEMPRANO ANRS 12136 Study Group. A trial of early antiretrovirals and isoniazid preventive therapy in Africa. N Engl J Med. 2015; 373(9):808-822.
4. Cohen MS, Chen YQ, McCauley M, et al.; HPTN 052 Study Team. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011; 365 (6):493-505.
5. Rodger A, Bruun T, Cambiano V, et al. HIV transmission risk through condomless sex if HIV+ partner on suppressive ART: PARTNER study. Presented at: Conference on Retroviruses and Opportunistic Infections; March 3-6, 2014; Boston, MA.
6. Canadian Task Force on the Periodic Health Examination. The periodic health examination. Can Med Assoc J. 1979; 121(9):1193-1254.
7. Thompson MA, Aberg JA, Hoy JF, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA. 2012; 308(4): 387-402.
8. Grinsztejn B, Hosseinipour MC, Ribaudo HJ, et al.; HPTN 052-ACTG Study Team. Effects of early vs delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial. Lancet Infect Dis. 2014; 14(4):281-290.
9. Panichsillapakit T, Smith DM, Wertheim JO, Richman DD, Little SJ, Mehta SR. Prevalence of transmitted HIV drug resistance among recently infected persons in San Diego, CA 1996-2013. J Acquir Immune Defic Syndr. 2016; 71(2):228-236.
10. Yang WL, Kouyos R, Scherrer AU, et al.; Swiss HIV Cohort Study. Assessing the paradox between transmitted and acquired HIV type 1 drug resistance mutations in the Swiss HIV Cohort Study from 1998 to 2012. J Infect Dis. 2015; 212(1):28-38.
11. Hofstra LM, Sauvageot N, Albert J, et al.; SPREAD Program. Transmission of HIV drug resistance and the predicted effect on current first-line regimens in Europe. Clin Infect Dis. 2016; 62(5):655-663.
12. Buzon MJ, Martin-Gayo E, Pereyra F, et al. Long-term antiretroviral treatment initiated at primary HIV-1 infection affects the size, composition, and decay kinetics of the reservoir of HIV-1-infected CD4 T cells. J Virol. 2014; 88(17): 10056-10065.
13. Ananworanich J, Schuetz A, Vandergeeten C, et al.; RV254/SEARCH 010 Study Group. Impact of multi-targeted antiretroviral treatment on gut T cell depletion and HIV reservoir seeding during acute HIV infection. PLoS One. 2012; 7(3):e33948.
14. Schuetz A, Deleage C, Sereti I, et al.; RV254/SEARCH 010 and RV304/SEARCH 013 Study Groups. Initiation of ART during early acute HIV infection preserves mucosal Th17 function and reverses HIV-related immune activation. PLoS Pathog. 2014; 10(4):e1004543.
15. Laanani M, Ghosn J, Essat A, et al.; Agence Nationale de Recherche sur le Sida PRIMO Cohort Study Group. Impact of the timing of initiation of antiretroviral therapy during primary HIV-1 infection on the decay of cell-associated HIV-DNA. Clin Infect Dis. 2015; 60(11):1715-1721.
16. Chéret A, Bacchus-Souffan C, Avettand-Fenoël V, et al; OPTIPRIM ANRS-147 Study Group. Combined ART started during acute HIV infection protects central memory CD4 T cells and can induce remission. J Antimicrob Chemother. 2015; 70(7):2108-2120.
17. El-Sadr WM, Lundgren J, Neaton JD, et al.; Strategies for Management of Antiretroviral Therapy Study Group. CD4 count-guided interruption of antiretroviral treatment. N Engl J Med. 2006; 355(22):2283-2296.
18. Marzel A, Shilaih M, Yang WL, et al.; Swiss HIV Cohort Study. HIV-1 transmission during recent infection and during treatment interruptions as major drivers of new infections in the Swiss HIV Cohort Study. Clin Infect Dis. 2016; 62(1):115-122.
19. Pilcher C, Hatano H, Dasgupta A, et al. Providing same day, observed ART to newly diagnosed HIV+ outpatients is associated with improved virologic suppression. Presented at: Eighth International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention; July 19-22, 2015; Vancouver, BC, Canada. Abstract WEAD0105 LB.
20. Rosen S, Maskew M, Fox MP, et al. Initiating ART at a patient's first clinic visit: the RapIT randomized trial. Presented at: 23rd Conference on Retroviruses and Opportunistic Infections; February 22-25, 2016; Boston, MA. Abstract 28.
21. Crowell TA, Gebo KA, Blankson JN, et al.; HIV Research Network. Hospitalization rates and reasons among HIV elite controllers and persons with medically controlled HIV infection. J Infect Dis. 2015; 211(11):1692-1702.
22. Simoni JM, Nance RM, Delaney JA, et al. HIV viral load in US clinics over time: trends and predictors from CNICS. Presented at: Conference on Retroviruses and Opportunistic Infections; February 22-25, 2016; Boston, MA.
23. Gisslen M, Svedhem V, Lindborg L, et al. The Swedish HIV treatement cascade. Presented at: Conference on Retroviruses and Opportunistic Infections; February 22-25, 2016; Boston, MA.
24. Moore DM, Cui Z, Lachowsky NJ, et al. Recent increases in virologic suppression among HIV-positive MSM in Vancouver, Canada. Presented at: Conference on Retroviruses and Opportunistic Infections; February 22-25, 2016; Boston, MA.
25. Gaolathe T, Wirth K, Holme MP, et al. Botswana is close to meeting UNAIDS 2020 goals of 90-90-90 coverage. Presented at: Conference on Retroviruses and Opportunistic Infections; February 22-25, 2016; Boston, MA.
26. Kohler P, Schmidt AJ, Cavassini M, et al.; Swiss HIV Cohort Study. The HIV care cascade in Switzerland: reaching the UNAIDS/WHO targets for patients diagnosed with HIV. AIDS. 2015; 29(18): 2509-2515.
27. Carpenter CCJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1996: recommendations of an international panel. JAMA. 1996; 276(2):146-154.
28. Carpenter CCJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1997: updated recommendations of the International AIDS Society-USA panel. JAMA. 1997; 277(24):1962-1969.
29. Carpenter CCJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA panel. JAMA. 1998; 280(1):78-86.
30. Carpenter CCJ, Cooper DA, Fischl MA, et al. Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA panel. JAMA. 2000; 283(3):381-390.
31. Yeni PG, Hammer SM, Carpenter CCJ, et al. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA panel. JAMA. 2002; 288(2):222-235.
32. Yeni PG, Hammer SM, Hirsch MS, et al. Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA panel. JAMA. 2004; 292(2):251-265.
33. Hammer SM, Saag MS, Schechter M, et al.; International AIDS Society-USA Panel. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA. 2006; 296(7):827-843.
34. Hammer SM, Eron JJ Jr, Reiss P, et al.; International AIDS Society-USA. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA. 2008; 300(5):555-570.
35. Thompson MA, Aberg JA, Cahn P, et al.; International AIDS Society-USA. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA. 2010; 304(3):321-333.
36. Walmsley SL, Antela A, Clumeck N, et al.; SINGLE Investigators. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. N Engl J Med. 2013; 369(19):1807-1818.
37. Clotet B, Feinberg J, van Lunzen J, et al.; ING114915 Study Team. Once-daily dolutegravir vs darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study. Lancet. 2014; 383(9936):2222-2231.
38. Squires K, Kityo C, Hodder S, et al. Elvitegravir (EVG)/cobicistat (COBI)/emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) is superior to ritonavir (RTV) boosted atazanavir (ATV) plus FTC/TDF in treatment naive women with HIV-1 infection (WAVES study). Presented at: Eighth International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention; July 18-22, 2015; Vancouver, BC, Canada. Abstract MOLBPE08.
39. Ofotokun I, Na LH, Landovitz RJ, et al.; AIDS Clinical Trials Group A5257 Team; AIDS Clinical Trials Group A5257 Team. Comparison of the metabolic effects of ritonavir-boosted darunavir or atazanavir vs raltegravir, and the impact of ritonavir plasma exposure: ACTG 5257. Clin Infect Dis. 2015; 60(12): 1842-1851.
40. Raffi F, Rachlis A, Stellbrink HJ, et al.; SPRING-2 Study Group. Once-daily dolutegravir vs raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet. 2013; 381(9868):735-743.
41. Cahn P, Pozniak AL, Mingrone H, et al.; Extended SAILING Study Team. Dolutegravir vs raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study. Lancet. 2013; 382 (9893):700-708.
42. Elion R, Molina JM, Ramón Arribas López J, et al; Study 145 Team. A randomized phase 3 study comparing once-daily elvitegravir with twice-daily raltegravir in treatment-experienced subjects with HIV-1 infection: 96-week results. J Acquir Immune Defic Syndr. 2013; 63(4):494-497.
43. Raffi F, Jaeger H, Quiros-Roldan E, et al.; Extended SPRING-2 Study Group. Once-daily dolutegravir vs twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial. Lancet Infect Dis. 2013; 13(11):927-935.
44. ∗5701 screening for hypersensitivity to abacavir. N Engl J Med. 2008; 358(6):568-579.
45. Sax PE, Tierney C, Collier AC, et al.; AIDS Clinical Trials Group Study A5202 Team. Abacavir-lamivudine vs tenofovir-emtricitabine for initial HIV-1 therapy. N Engl J Med. 2009; 361(23):2230-2240.
46. Post FA, Moyle GJ, Stellbrink HJ, et al. Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine vs tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study. J Acquir Immune Defic Syndr. 2010; 55(1):49-57.
47. Marcus JL, Neugebauer RS, Leyden WA, et al. Use of abacavir and risk of cardiovascular disease among HIV-infected individuals. J Acquir Immune Defic Syndr. 2016; 71(4):413-419.
48. Young J, Xiao Y, Moodie EE, et al.; Swiss HIV Cohort Study. Effect of cumulating exposure to abacavir on the risk of cardiovascular disease events in patients from the Swiss HIV Cohort Study. J Acquir Immune Defic Syndr. 2015; 69(4):413-421.
49. Sabin CA, Reiss P, Ryom L, et al.; D:A:D Study Group. Is there continued evidence for an association between abacavir usage and myocardial infarction risk in individuals with HIV? a cohort collaboration. BMC Med. 2016; 14(1):61.
50. Kovari H, Sabin CA, Ledergerber B, et al. Antiretroviral drugs and risk of chronic alanine aminotransferase elevation in human immunodeficiency virus (HIV)-monoinfected persons: the Data Collection on Adverse Events of Anti-HIV Drugs study. Open Forum Infect Dis. 2016; 3(4):ofw009.
51. Sax PE, Wohl D, Yin MT, et al.; GS-US-292-0104/0111 Study Team. Tenofovir alafenamide vs tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet. 2015; 385(9987): 2606-2615.
52. Wohl D, Oka S, Clumeck N, et al.; GS-US-292-01040111 and Study Team. Brief report: a randomized, double-blind comparison of tenofovir alafenamide versus tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine for initial HIV-1 treatment: week 96 results. J Acquir Immune Defic Syndr. 2016; 72(1):58-64.
53. Mills A, Arribas JR, Andrade-Villanueva J, et al.; GS-US-292-0109 Team. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study. Lancet Infect Dis. 2016; 16(1): 43-52.
54. Gallant J, Daar E, Raffi F, et al. Switching tenofovir DF to tenofovir alafenamide in virologically suppressed adults. Presented at: 23rd Conference on Retroviruses and Opportunistic Infections; February 22-25, 2016; Boston, MA.
55. Mollan KR, Smurzynski M, Eron JJ, et al. Association between efavirenz as initial therapy for HIV-1 infection and increased risk for suicidal ideation or attempted or completed suicide: an analysis of trial data. Ann Intern Med. 2014; 161(1):1-10.
56. Girouard MP, Sax PE, Parker RA, et al. The cost-effectiveness and budget impact of 2-drug dolutegravir-lamivudine regimens for the treatment of HIV infection in the United States. Clin Infect Dis. 2016; 62(6):784-791.
57. Cahn P, Andrade-Villanueva J, Arribas JR, et al.; GARDEL Study Group. Dual therapy with lopinavir and ritonavir plus lamivudine vs triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial. Lancet Infect Dis. 2014; 14(7):572-580.
58. Raffi F, Babiker AG, Richert L, et al.; NEAT001/ANRS143 Study Group. Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial. Lancet. 2014; 384 (9958):1942-1951.
59. Figueroa MI, Sued O, Patterson P, et al. Dolutegravir-lamivudine as initial therapy in HIV-infected, ARV naive patients: first results of the PADDLE trial. Presented at: 15th European AIDS Conference; October 21-24, 2015; Barcelona, Spain. Abstract LBPS4/1.
60. Gallant JE, Daar ES, Raffi F, et al. Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial. Lancet HIV. 2016; 3(4):e158-e165.
61. Buti M, Gane E, Seto WK, et al. A phase 3 study of tenofovir alafenamide compared with tenofovir disoproxil fumarate in patients with HBeAg-negative, chronic hepatitis B: week 48 efficacy and safety results. Presented at: International Liver Congress; April 13-17, 2016; Barcelona, Spain. Abstract GS06.
62. Chan HLY, Fung S, Seto WK, et al. A phase 3 study of tenofovir alafenamide compared with tenofovir disoproxil fumarate in patients with HBeAg-positive chronic HBV: week 48 efficacy and safety results. Presented at: International Liver Congress; April 13-17, 2016; Barcelona, Spain. Abstract GS12.
63. American Association for the Study of Liver Diseases and Infectious Diseases Society of America. HCV guidance: recommendations for testing, managing, and treating hepatitis C. http://hcvguidelines.org/. Accessed April 20, 2016.
64. Borges AH, Hoy J, Florence E, et al. Antiretrovirals, fractures, and osteonecrosis in a large European HIV cohort. Presented at: 23rd Conference on Retroviruses and Opportunistic Infections; February 22-25, 2016; Boston, MA. Abstract 46.
65. Lucas GM, Ross MJ, Stock PG, et al.; HIV Medicine Association of the Infectious Diseases Society of America. Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2014; 59(9):e96-e138.
66. Mocroft A, Lundgren JD, Ross M, et al.; Data Collection on Adverse events of Anti-HIV Drugs (D:A:D) Study. Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study. Lancet HIV. 2016; 3(1): e23-e32.
67. Pozniak A, Arribas JR, Gupta SK, et al. Safety of tenofovir alafenamide in renal impairment. Presented at: 22nd Conference on Retroviruses and Opportunistic Infections; February 23-26, 2015; Seattle, WA.
68. Chen RY, Accortt NA, Westfall AO, et al. Distribution of health care expenditures for HIV-infected patients. Clin Infect Dis. 2006; 42(7): 1003-1010.
69. Freedberg KA, Losina E, Weinstein MC, et al. The cost effectiveness of combination antiretroviral therapy for HIV disease. N Engl J Med. 2001; 344 (11):824-831.
70. Walensky RP, Sax PE, Nakamura YM, et al. Economic savings vs health losses: the cost-effectiveness of generic antiretroviral therapy in the United States. Ann Intern Med. 2013; 158(2): 84-92.
71. Walmsley S, Baumgarten A, Berenguer J, et al. Brief report: dolutegravir plus abacavir/lamivudine for the treatment of HIV-1 infection in antiretroviral therapy-naive patients: week 96 and week 144 results from the SINGLE randomized clinical trial. J Acquir Immune Defic Syndr. 2015; 70(5):515-519.
72. Boulware DR, Meya DB, Muzoora C, et al.; COAT Trial Team. Timing of antiretroviral therapy after diagnosis of cryptococcal meningitis. N Engl J Med. 2014; 370(26):2487-2498.
73. Perfect JR, Dismukes WE, Dromer F, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2010; 50(3):291-322.
74. Ingle SM, Miro JM, Furrer H, et al. Impact of ART on mortality in cryptococcal meningitis patients: high-income settings. Presented at: 22nd Conference on Retroviruses and Opportunistic Infections; February 23-26, 2015; Seattle, WA.
75. Mfinanga SG, Kirenga BJ, Chanda DM, et al. Early vs delayed initiation of highly active antiretroviral therapy for HIV-positive adults with newly diagnosed pulmonary tuberculosis (TB-HAART): a prospective, international, randomised, placebo-controlled trial. Lancet Infect Dis. 2014; 14(7):563-571.
76. Blanc FX, Sok T, Laureillard D, et al.; CAMELIA (ANRS 1295-CIPRA KH001) Study Team. Earlier vs later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med. 2011; 365 (16):1471-1481.
77. Havlir DV, Kendall MA, Ive P, et al.; AIDS Clinical Trials Group Study A5221. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med. 2011; 365(16):1482-1491.
78. Abdool Karim S, Naidoo K, Padayatchi N, et al. Optimal timing of ART during TB therapy: findings of the SAPiT trial. Presented at: 18th Conference on Retroviruses and Opportunistic Infections. February 27-March 2, 2011; Boston, MA.
79. Manzardo C, Guardo AC, Letang E, Plana M, Gatell JM, Miro JM. Opportunistic infections and immune reconstitution inflammatory syndrome in HIV-1-infected adults in the combined antiretroviral therapy era: a comprehensive review. Expert Rev Anti Infect Ther. 2015; 13(6):751-767.
80. Luetkemeyer AF, Rosenkranz SL, Lu D, et al.; Adult AIDS Clinical Trials Group A5221 Study Team. Relationship between weight, efavirenz exposure, and virologic suppression in HIV-infected patients on rifampin-based tuberculosis treatment in the AIDS Clinical Trials Group A5221 STRIDE Study. Clin Infect Dis. 2013; 57(4):586-593.
81. Grinsztejn B, De Castro N, Arnold V, et al.; ANRS 12 180 Reflate TB Study Group. Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial. Lancet Infect Dis. 2014; 14(6):459-467.
82. Dooley KE, Sayre P, Borland J, et al. Safety, tolerability, and pharmacokinetics of the HIV integrase inhibitor dolutegravir given twice daily with rifampin or once daily with rifabutin: results of a phase 1 study among healthy subjects. J Acquir Immune Defic Syndr. 2013; 62(1):21-27.
83. Friedland G, Khoo S, Jack C, Lalloo U. Administration of efavirenz (600 mg/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV. J Antimicrob Chemother. 2006; 58(6):1299-1302.
84. Naiker S, Conolly C, Weisner L, et al. Pharmacokinetic evaluation of different rifabutin dosing strategies in African TB patients on lopinavir/ritonavir-based ART. Presented at: 18th Conference on Retroviruses and Opportunistic Infections; February 27-March 2, 2011; Boston, MA.
85. Boulanger C, Hollender E, Farrell K, et al. Pharmacokinetic evaluation of rifabutin in combination with lopinavir-ritonavir in patients with HIV infection and active tuberculosis. Clin Infect Dis. 2009; 49(9):1305-1311.
86. Jenny-Avital ER, Joseph K. Rifamycin-resistant Mycobacterium tuberculosis in the highly active antiretroviral therapy era: a report of 3 relapses with acquired rifampin resistance following alternate-day rifabutin and boosted protease inhibitor therapy. Clin Infect Dis. 2009; 48(10):1471-1474.
87. Sterling TR, Scott NA, Miro JM, et al.; Tuberculosis Trials Consortium, the AIDS Clinical Trials Group for the PREVENT TB Trial (TBTC Study 26ACTG 5259). Three months of weekly rifapentine and isoniazid for treatment of Mycobacterium tuberculosis infection in HIV-coinfected persons. AIDS. 2016; 30(10):1607-1615.
88. Centers for Disease Control and Prevention. Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent Mycobacterium tuberculosis infection. MMWR Morb Mortal Wkly Rep. 2011; 60(48):1650-1653.
89. Sterling T, Benson C, Scott N, et al. Three months of weekly rifapentine + INH for M tuberculosis infection in HIV-infected persons [CROI abstract 817]. Top Antivir Med. 2014; 22(e-1):425.
90. Diacon AH, Pym A, Grobusch M, et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med. 2009; 360(23):2397-2405.
91. Weiner M, Egelund EF, Engle M, et al. Pharmacokinetic interaction of rifapentine and raltegravir in healthy volunteers. J Antimicrob Chemother. 2014; 69(4):1079-1085.
92. Djawe K, Buchacz K, Hsu L, et al. Mortality risk after AIDS-defining opportunistic illness among HIV-infected persons - San Francisco, 1981-2012. J Infect Dis. 2015; 212(9):1366-1375.
93. Yangco BG, Buchacz K, Baker R, Palella FJ, Armon C, Brooks JT; HIV Outpatient Study Investigators. Is primary Mycobacterium avium complex prophylaxis necessary in patients with CD4 <50 cells/μL who are virologically suppressed on cART? AIDS Patient Care STDS. 2014; 28(6):280-283.
94. Mocroft A, Reiss P, Kirk O, et al.; Opportunistic Infections Project Team of the Collaboration of Observational HIV Epidemiological Research in Europe. Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count <200 cells/μL? Clin Infect Dis. 2010; 51(5):611-619.
95. Trottier B, Lake J, Logue K, et al. Switching to abacavir/dolutegravir/lamivudine combination (ABC/DTG/3TC FDC) from a PI, INI or NNRTI based regimen maintains HIV suppression. Presented at: Interscience Conference on Antimicrobial Agents and Chemotherapy; September 17-21, 2015; San Diego, CA.
96. Pozniak A, Markowitz M, Mills A, et al. Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir vs continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week results of a randomised, open-label, phase 3b non-inferiority trial. Lancet Infect Dis. 2014; 14(7): 590-599.
97. Arribas JR, Pialoux G, Gathe J, et al. Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir vs continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results of a randomised, open-label, phase 3b, non-inferiority trial. Lancet Infect Dis. 2014; 14(7): 581-589.
98. Palella FJ Jr, Fisher M, Tebas P, et al. Simplification to rilpivirine/emtricitabine/tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1 RNA-suppressed participants. AIDS. 2014; 28(3):335-344.
99. Perez-Molina JA, Rubio R, Rivero A, et al.; GESIDA 7011 Study Group. Dual treatment with atazanavir-ritonavir plus lamivudine vs triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial. Lancet Infect Dis. 2015; 15(7):775-784.
100. Arribas JR, Girard PM, Landman R, et al.; OLE/RIS-EST13 Study Group. Dual treatment with lopinavir-ritonavir plus lamivudine vs triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial. Lancet Infect Dis. 2015; 15(7): 785-792.
101. Margolis DA, Brinson CC, Smith GH, et al.; LAI116482 Study Team. Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial. Lancet Infect Dis. 2015; 15(10): 1145-1155.
102. Calcagno A, Montrucchio C, Capetti A, et al. Raltegravir plus nevirapine as maintenance antiretroviral therapy in HIV-positive patients: safety, efficacy and pharmacokinetics. Curr HIV Res. 2016; 14(1):54-60.
103. Eron JJ, Young B, Cooper DA, et al.; SWITCHMRK 1 and 2 Investigators. Switch to a raltegravir-based regimen vs continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials. Lancet. 2010; 375(9712):396-407.
104. Derache A, Shin HS, Balamane M, et al. HIV drug resistance mutations in proviral DNA from a community treatment program. PLoS One. 2015; 10 (1):e0117430.
105. Lübke N, Di Cristanziano V, Sierra S, et al. Proviral DNA as a target for HIV-1 resistance analysis. Intervirology. 2015; 58(3):184-189.
106. Toma J, Tan Y, Cai S, et al. Drug resistance profiles derived from HIV-1 DNA in ARV suppressed patients correlate with historical resistance profiles obtained from HIV-1 plasma RNA. Presented at: Interscience Conference on Antimicrobial Agents and Chemotherapy; September 17-21, 2015; San Diego, CA.
107. Volpe JM, Yang O, Petropoulos CJ, Walworth CM. Absence of integrase inhibitor resistant HIV-1 transmission in the California AIDS Healthcare Foundation Network. Presented at: Interscience Conference on Antimicrobial Agents and Chemotherapy; September 17-21, 2015; San Diego, CA.
108. Casadellà M, van Ham PM, Noguera-Julian M, et al; SPREAD Programme. Primary resistance to integrase strand-transfer inhibitors in Europe. J Antimicrob Chemother. 2015; 70(10):2885-2888.
109. Scherrer AU, Yang WL, Kouyos RD, et al.; Swiss HIV Cohort Study. Successful prevention of transmission of integrase resistance in the Swiss HIV Cohort Study [published online April 29, 2016]. J Infect Dis.
110. Aberg JA, Gallant JE, Ghanem KG, Emmanuel P, Zingman BS, Horberg MA; Infectious Diseases Society of America. Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2014; 58(1):1-10.
111. European AIDS Clinical Society. European AIDS Clinical Society Guidelines 8.0. http://www.eacsociety.org/files/2015-eacsguidelines-8-0-english-rev-20160124.pdf. Accessed April 8, 2016.
112. Crowell TA, Phanuphak N, Pinyakorn S, et al. Virologic failure is uncommon after treatment is initiated during acute HIV infection. Presented at: Conference on Retroviruses and Opportunistic Infections; February 22-25, 2016; Boston, MA.
113. Sax PE Editorial commentary: can we break the habit of routine CD4 monitoring in HIV care? Clin Infect Dis. 2013; 56(9):1344-1346.
114. Workowski KA, Bolan GA; Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep. 2015; 64(RR-03):1-137.
115. Henrich TJ, Wood BR, Kuritzkes DR. Increased risk of virologic rebound in patients on antiviral therapy with a detectable HIV load <48 copies/mL. PLoS One. 2012; 7(11):e50065.
116. Young J, Rickenbach M, Calmy A, et al.; Swiss HIV Cohort Study. Transient detectable viremia and the risk of viral rebound in patients from the Swiss HIV Cohort Study. BMC Infect Dis. 2015; 15:382.
117. Teira R, Munoz-Sanchez M, Suarez-Lozano I, et al. Effect of viral suppression below 20 copies of HIV-RNA per millilitre of plasma on virological outcome of treated HIV-infected patients. Presented at: 20th International AIDS Conference; July 20-25, 2014; Melbourne, Australia.
118. Ryscavage P, Kelly S, Li JZ, Harrigan PR, Taiwo B. Significance and clinical management of persistent low-level viremia and very-low-level viremia in HIV-1-infected patients. Antimicrob Agents Chemother. 2014; 58(7):3585-3598.
119. Boillat-Blanco N, Darling KE, Schoni-Affolter F, et al.; Swiss HIV Cohort Study. Virological outcome and management of persistent low-level viraemia in HIV-1-infected patients: 11 years of the Swiss HIV Cohort Study. Antivir Ther. 2015; 20(2):165-175.
120. Jain V, Sucupira MC, Bacchetti P, et al. Differential persistence of transmitted HIV-1 drug resistance mutation classes. J Infect Dis. 2011; 203 (8):1174-1181.
121. Pingen M, Wensing AM, Fransen K, et al.; SPREAD Programme. Persistence of frequently transmitted drug-resistant HIV-1 variants can be explained by high viral replication capacity. Retrovirology. 2014; 11:105.
122. Yang WL, Kouyos RD, Böni J, et al.; Swiss HIV Cohort Study. Persistence of transmitted HIV-1 drug resistance mutations associated with fitness costs and viral genetic backgrounds. PLoS Pathog. 2015; 11 (3):e1004722.
123. Baxter JD, Dunn D, White E, et al.; International Network for Strategic Initiatives in Global HIV Trials START Study Group. Global HIV-1 transmitted drug resistance in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. HIV Med. 2015; 16(SUPPL. 1):77-87.
124. Lepik K, Yip B, Robbins MA, et al. Prevalence and incidence of integrase drug resistance in BC, Canada, 2009-2015. Presented at: Conference on Retroviruses and Opportunistic Infections; February 22-25, 2016; Boston, MA.
125. Lesko CR, Cole SR, Zinski A, Poole C, Mugavero MJ. A systematic review and meta-regression of temporal trends in adult CD4(+) cell count at presentation to HIV care, 1992-2011. Clin Infect Dis. 2013; 57(7):1027-1037.
126. Siedner MJ, Ng CK, Bassett IV, Katz IT, Bangsberg DR, Tsai AC. Trends in CD4 count at presentation to care and treatment initiation in sub-Saharan Africa, 2002-2013: a meta-analysis. Clin Infect Dis. 2015; 60(7):1120-1127.
127. Champenois K, Cousien A, Cuzin L, et al. Missed opportunities for HIV testing in newly HIV-diagnosed patients: a cross sectional study. BMC Infect Dis. 2013; 13:200.
128. US Preventive Services Task Force. Human immunodeficiency virus (HIV) infection: screening. http://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/human-immunodeficiency-virus-hiv-infection-screening. Accessed April 20, 2016.
129. Branson BM, Handsfield HH, Lampe MA, et al.; Centers for Disease Control and Prevention. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep. 2006; 55(RR-14):1-17.
130. Skarbinski J, Rosenberg E, Paz-Bailey G, et al. Human immunodeficiency virus transmission at each step of the care continuum in the United States. JAMA Intern Med. 2015; 175(4):588-596.
131. Magnus M, Herwehe J, Gruber D, et al. Improved HIV-related outcomes associated with implementation of a novel public health information exchange. Int J Med Inform. 2012; 81 (10):e30-e38.
132. Christopoulos KA, Scheer S, Steward WT, et al. Examining clinic-based and public health approaches to ascertainment of HIV care status. J Acquir Immune Defic Syndr. 2015; 69(SUPPL. 1):S56-S62.
133. Marks G, Gardner LI, Craw J, Crepaz N. Entry and retention in medical care among HIV-diagnosed persons: a meta-analysis. AIDS. 2010; 24(17):2665-2678.
134. Thompson MA, Mugavero MJ, Amico KR, et al. Guidelines for improving entry into and retention in care and antiretroviral adherence for persons with HIV: evidence-based recommendations from an International Association of Physicians in AIDS Care panel. Ann Intern Med. 2012; 156(11):817-833, W-284-W-294.
135. Centers for Disease Control and Prevention. Compendium of evidence-based interventions and best practices for HIV prevention. http://www.cdc.gov/hiv/research/interventionresearch/compendium/lrc/index.html. Accessed April 7, 2016.
136. Gardner LI, Metsch LR, Anderson-Mahoney P, et al.; Antiretroviral Treatment and Access Study Group. Efficacy of a brief case management intervention to link recently diagnosed HIV-infected persons to care. AIDS. 2005; 19(4):423-431.
137. Craw JA, Gardner LI, Marks G, et al. Brief strengths-based case management promotes entry into HIV medical care: results of the antiretroviral treatment access study-II. J Acquir Immune Defic Syndr. 2008; 47(5):597-606.
138. Bradford JB, Coleman S, Cunningham W. HIV system navigation: an emerging model to improve HIV care access. AIDS Patient Care STDS. 2007; 21 (SUPPL. 1):S49-S58.
139. Naar-King S, Bradford J, Coleman S, Green-Jones M, Cabral H, Tobias C. Retention in care of persons newly diagnosed with HIV: outcomes of the Outreach Initiative. AIDS Patient Care STDS. 2007; 21(SUPPL. 1):S40-S48.
140. Metsch LR, Feaster DJ, Gooden L, et al. A patient navigation/contingency management RCT for hospitalized HIV+ substance users. Presented at: Conference on Retroviruses and Opportunistic Infections; February 22-25, 2016; Boston, MA.
141. Berg KM, Litwin A, Li X, Heo M, Arnsten JH. Directly observed antiretroviral therapy improves adherence and viral load in drug users attending methadone maintenance clinics: a randomized controlled trial. Drug Alcohol Depend. 2011; 113(2-3): 192-199.
142. Maru DS, Bruce RD, Walton M, Springer SA, Altice FL. Persistence of virological benefits following directly administered antiretroviral therapy among drug users: results from a randomized controlled trial. J Acquir Immune Defic Syndr. 2009; 50(2):176-181.
143. Babudieri S, Aceti A, D'Offizi GP, Carbonara S, Starnini G. Directly observed therapy to treat HIV infection in prisoners. JAMA. 2000; 284(2):179-180.
144. Mugavero MJ, Westfall AO, Cole SR, et al.; Centers for AIDS Research Network of Integrated Clinical Systems. Beyond core indicators of retention in HIV care: missed clinic visits are independently associated with all-cause mortality. Clin Infect Dis. 2014; 59(10):1471-1479.
145. Lester RT, Ritvo P, Mills EJ, et al. Effects of a mobile phone short message service on antiretroviral treatment adherence in Kenya (WelTel Kenya1): a randomised trial. Lancet. 2010; 376(9755):1838-1845.
146. Gardner LI, Giordano TP, Marks G, et al.; Retention in Care Study Group. Enhanced personal contact with HIV patients improves retention in primary care: a randomized trial in 6 US HIV clinics. Clin Infect Dis. 2014; 59(5):725-734.
147. Glass TR, Sterne JA, Schneider MP, et al.; Swiss HIV Cohort Study. Self-reported nonadherence to antiretroviral therapy as a predictor of viral failure and mortality. AIDS. 2015; 29(16):2195-2200.
148. Feldman BJ, Fredericksen RJ, Crane PK, et al. Evaluation of the single-item self-rating adherence scale for use in routine clinical care of people living with HIV. AIDS Behav. 2013; 17(1):307-318.
149. Nosyk B, Min JE, Colley G, et al. The causal effect of opioid substitution treatment on HAART medication refill adherence. AIDS. 2015; 29(8):965-973.
150. Sin NL, DiMatteo MR. Depression treatment enhances adherence to antiretroviral therapy: a meta-analysis. Ann Behav Med. 2014; 47(3):259-269.
151. Gaynes BN, Pence BW, Atashili J, et al. Changes in HIV outcomes following depression care in a resource-limited setting: results from a pilot study in Bamenda, Cameroon. PLoS One. 2015; 10(10): e0140001.
152. Pence BW, Gaynes BN, Adams JL, et al. The effect of antidepressant treatment on HIV and depression outcomes: results from a randomized trial. AIDS. 2015; 29(15):1975-1986.
153. Pyne JM, Fortney JC, Curran GM, et al. Effectiveness of collaborative care for depression in human immunodeficiency virus clinics. Arch Intern Med. 2011; 171(1):23-31.
154. Tsai AC, Karasic DH, Hammer GP, et al. Directly observed antidepressant medication treatment and HIV outcomes among homeless and marginally housed HIV-positive adults: a randomized controlled trial. Am J Public Health. 2013; 103(2): 308-315.
155. Safren SA, O'Cleirigh C, Tan JY, et al. A randomized controlled trial of cognitive behavioral therapy for adherence and depression (CBT-AD) in HIV-infected individuals. Health Psychol. 2009; 28(1):1-10.
156. Safren SA, O'Cleirigh CM, Bullis JR, Otto MW, Stein MD, Pollack MH. Cognitive behavioral therapy for adherence and depression (CBT-AD) in HIV-infected injection drug users: a randomized controlled trial. J Consult Clin Psychol. 2012; 80(3): 404-415.
157. Simoni JM, Wiebe JS, Sauceda JA, et al. A preliminary RCT of CBT-AD for adherence and depression among HIV-positive Latinos on the U.S.-Mexico border: the Nuevo Día study. AIDS Behav. 2013; 17(8):2816-2829.
158. Townsend CL, Byrne L, Cortina-Borja M, et al. Earlier initiation of ART and further decline in mother-to-child HIV transmission rates, 2000-2011. AIDS. 2014; 28(7):1049-1057.
159. Forbes JC, Alimenti AM, Singer J, et al.; Canadian Pediatric AIDS Research Group. A national review of vertical HIV transmission. AIDS. 2012; 26 (6):757-763.
160. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment: Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med. 1994; 331(18):1173-1180.
161. Kitahata MM, Gange SJ, Abraham AG, et al.; NA-ACCORD Investigators. Effect of early vs deferred antiretroviral therapy for HIV on survival. N Engl J Med. 2009; 360(18):1815-1826.
162. Donnell D, Baeten JM, Kiarie J, et al.; Partners in Prevention HSV/HIV Transmission Study Team. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet. 2010; 375(9731):2092-2098.
163. Cohen M, Chen Y, McCauley M, et al. Final results of the HPTN 052 randomized controlled trial: antiretroviral therapy prevents HIV transmission. Presented at: Eighth International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment, and Prevention; July 19-22, 2015; Vancouver, BC, Canada. Abstract MOAC0101LB.
164. Bavinton BR, Jin F, Prestage G, et al.; Opposites Attract Study Group. The Opposites Attract Study of viral load, HIV treatment and HIV transmission in serodiscordant homosexual male couples: design and methods. BMC Public Health. 2014; 14:917.
165. Centers for Disease Control and Prevention. Preexposure prophylaxis for the prevention of HIV infection in the United States - 2014: a clinical practice guideline. http://www.cdc.gov/hiv/pdf/guidelines/PrEPguidelines2014.pdf. Accessed March 10, 2016.
166. World Health Organization. Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. http://apps.who.int/iris/bitstream/10665/186275/1/9789241509565-eng.pdf. Accessed May 10, 2016.
167. Marrazzo JM, del Rio C, Holtgrave DR, et al.; International Antiviral Society-USA Panel. HIV prevention in clinical care settings: 2014 recommendations of the International Antiviral Society-USA Panel. JAMA. 2014; 312(4):390-409.
168. Grant RM, Lama JR, Anderson PL, et al.; iPrEx Study Team. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010; 363(27):2587-2599.
169. Grant RM, Anderson PL, McMahan V, et al.; iPrEx Study Team. Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. Lancet Infect Dis. 2014; 14(9): 820-829.
170. Volk JE, Marcus JL, Phengrasamy T, et al. No new HIV infections with increasing use of HIV preexposure prophylaxis in a clinical practice setting. Clin Infect Dis. 2015; 61(10):1601-1603.
171. McCormack S, Dunn DT, Desai M, et al. Pre-exposure Prophylaxis to Prevent the Acquisition of HIV-1 Infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet. 2016; 387(10013):53-60.
172. Baeten JM, Donnell D, Ndase P, et al.; Partners PrEP Study Team. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012; 367(5):399-410.
173. Thigpen MC, Kebaabetswe PM, Paxton LA, et al.; TDF2 Study Group. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012; 367(5):423-434.
174. Molina J-M, Charreau I, Spire B, et al. On demand PrEP with oral TDF-FTC in the open-label phase of the ANRS IPERGAY trial. Presented at: 23rd Conference on Retroviruses and Opportunistic Infections; February 22-25, 2016; Boston, MA.
175. Molina JM, Capitant C, Spire B, et al.; ANRS IPERGAY Study Group. On-demand preexposure prophylaxis in men at high risk for HIV-1 infection. N Engl J Med. 2015; 373(23):2237-2246.
176. Liu AY, Cohen SE, Vittinghoff E, et al. Preexposure prophylaxis for HIV infection integrated with municipal- and community-based sexual health services. JAMA Intern Med. 2016; 176 (1):75-84.
177. Molina JM Coitally dependent TDF/FTC in MSM: updates on PrEP efficacy in IPERGAY. Presented at: Eighth International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention; July 19-22, 2015; Vancouver, BC, Canada.
178. Cottrell ML, Yang KH, Prince HM, et al. A translational pharmacology approach to predicting outcomes of preexposure prophylaxis against HIV in men and women using tenofovir disoproxil fumarate with or without emtricitabine. J Infect Dis. 2016; 214(1):55-64.
179. Choopanya K, Martin M, Suntharasamai P, et al.; Bangkok Tenofovir Study Group. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2013; 381 (9883):2083-2090.
180. Deutsch MB, Mendez MF. Neurocognitive features distinguishing primary central nervous system lymphoma from other possible causes of rapidly progressive dementia. Cogn Behav Neurol. 2015; 28(1):1-10.
181. Gandhi M, Glidden D, Liu AY, et al. Higher cumulative TFV/FTC levels in PrEP associated with decline in renal function. Presented at: Conference on Retroviruses and Opportunistic Infections; February 22-25, 2016; Boston, MA.
182. Liu AY, Vittinghoff E, Anderson PL, et al. Changes in renal function associated with TDF/FTC PrEP use in the US Demo Project. Presented at: Conference on Retroviruses and Opportunistic Infections; February 22-25, 2016; Boston, MA.
183. Solomon MM, Lama JR, Glidden DV, et al.; iPrEx Study Team. Changes in renal function associated with oral emtricitabine/tenofovir disoproxil fumarate use for HIV pre-exposure prophylaxis. AIDS. 2014; 28(6):851-859.
184. Mugwanya KK, Wyatt C, Celum C, et al.; Partners PrEP Study Team. Changes in glomerular kidney function among HIV-1-uninfected men and women receiving emtricitabine-tenofovir disoproxil fumarate preexposure prophylaxis: a randomized clinical trial. JAMA Intern Med. 2015; 175(2):246-254.
185. Liu AY, Vittinghoff E, Sellmeyer DE, et al. Bone mineral density in HIV-negative men participating in a tenofovir pre-exposure prophylaxis randomized clinical trial in San Francisco. PLoS One. 2011; 6(8): e23688.
186. Kasonde M, Niska RW, Rose C, et al. Bone mineral density changes among HIV-uninfected young adults in a randomised trial of pre-exposure prophylaxis with tenofovir-emtricitabine or placebo in Botswana. PLoS One. 2014; 9(3):e90111.
187. Mulligan M, Rutledge B, Kapogiannis BG, et al. Bone changes in young men ages 18-22 enrolled in a pre-exposure prophylaxis (PrEP) safety and demonstration study using tenofovir disoproxil fumarate/emtricitabine (TDF/FTC). Presented at: 15th European AIDS Conference; October 21-24, 2015; Barcelona, Spain.
188. Grant R, Mulligan K, McMahan V, et al. Recovery of bone mineral density after stopping oral HIV preexposure prophylaxis. Presented at: Conference on Retroviruses and Opportunistic Infections; February 22-25, 2016; Boston, MA.
189. Markowitz LE, Dunne EF, Saraiya M, et al.; Centers for Disease Control and Prevention. Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2014; 63(RR-05):1-30.
190. Golub SA, Pena S, Boonrai K, et al. STI data from community-based PrEP implementation suggest changes to CDC guidelines. Presented at: 23rd Conference on Retroviruses and Opportunistic Infections; February 22-25, 2016; Boston, MA. Abstract 869.
191. Liu AY, Vittinghoff E, Anderson PL, et al. Changes in renal function associated with TDF/FTC PrEP use in the US Demo Project. Presented at: Conference on Retroviruses and Opportunistic Infections; February 22-25, 2016; Boston, MA.
192. Knox DC, Tan DH, Harrigan PR, Anderson PL. HIV-1 infection with multiclass resistance despite preexposure prophylaxis (PrEP). Presented at: Conference on Retroviruses and Opportunistic Infections; February 22-25, 2016; Boston, MA.
193. Massud I, Mitchell J, Babusis D, et al. Chemoprophylaxis with oral FTC/TAF protects macaques from rectal SHIV infection. Presented at: Conference on Retroviruses and Opportunistic Infections; February 22-25, 2016; Boston, MA.
194. Garrett KL, Cottrell ML, Prince HM, et al. Concentrations of TFV and TFVdp in female mucosal tissues after a single dose of TAF. Presented at: Conference on Retroviruses and Opportunistic Infections; February 22-25, 2016; Boston, MA.
195. Cardo DM, Culver DH, Ciesielski CA, et al.; Centers for Disease Control and Prevention Needlestick Surveillance Group. A case-control study of HIV seroconversion in health care workers after percutaneous exposure. N Engl J Med. 1997; 337(21):1485-1490.
196. Centers for Disease Control and Prevention. Updated guidelines for antiretroviral postexposure prophylaxis after sexual, injection drug use, or other nonoccupational exposure to HIV - United States, 2016. http://www.cdc.gov/hiv/pdf/programresources/cdc-hiv-npep-guidelines.pdf. Accessed April 22, 2016.
197. Margolis DA, Gonzalez-Garcia J, Stellbrink HJ, et al. Cabotegravir + rilpivirine as long-acting maintenance therapy: LATTE-2 week 32 results. Presented at: Conference on Retroviruses and Opportunistic Infections; February 22-25, 2016; Boston, MA.
198. Friedman E, Schuermann D, Rudd DJ, et al. A single monotherapy dose of MK-8591, a novel NRTI, suppresses HIV for 10 days. Presented at: Conference on Retroviruses and Opportunistic Infections; February 22-25, 2016; Boston, MA.
199. Grobler J, Friedman E, Barrett SE, et al. Long-acting oral and parenteral dosing of MK-8591 for HIV treatment or prophylaxis. Presented at: Conference on Retroviruses and Opportunistic Infections; February 22-25, 2016; Boston, MA.
200. Markowitz M, Frank I, Grant R, et al. ÉCLAIR: phase 2A safety and PK study of cabotegravir LA in HIV-uninfected men. Presented at: 23rd Conference on Retroviruses and Opportunistic Infections; February 22-25, 2016; Boston, MA. Abstract 106.
201. Baeten JM, Palanee-Phillips T, Brown ER, et al.; MTN-020-ASPIRE Study Team. Use of a vaginal ring containing dapivirine for HIV-1 prevention in women [published online February 22, 2016]. N Engl J Med.
202. Nel A, Kapiga S, Bekker LG, et al. Safety and efficacy of dapivirine vaginal ring for HIV-1 prevention in African women. Presented at: 23rd Conference on Retroviruses and Opportunistic Infections; February 22-25, 2016; Boston, MA. Abstract 110LB.
203. Lynch RM, Boritz E, Coates EE, et al.; VRC 601 Study Team. Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection. Sci Transl Med. 2015; 7(319): 319ra206.
204. Caskey M, Klein F, Lorenzi JC, et al. Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Nature. 2015; 522 (7557):487-491.
205. Stephenson KE, Barouch DH. Broadly neutralizing antibodies for HIV eradication. Curr HIV/AIDS Rep. 2016; 13(1):31-37.
206. Moldt B, Le K, Carnathan DG, et al. Neutralizing antibody affords comparable protection against vaginal and rectal SHIV challenge in macaques [published online March 21, 2016]. AIDS.
207. Richman DD, Margolis DM, Delaney M, Greene WC, Hazuda D, Pomerantz RJ. The challenge of finding a cure for HIV infection. Science. 2009; 323(5919):1304-1307.
208. Qin XF, An DS, Chen IS, Baltimore D. Inhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5. Proc Natl Acad Sci U S A. 2003; 100(1):183-188.
209. Burke BP, Levin BR, Zhang J, et al. Engineering cellular resistance to HIV-1 infection in vivo using a dual therapeutic lentiviral vector. Mol Ther Nucleic Acids. 2015; 4:e236.
210. Wolstein O, Boyd M, Millington M, et al. Preclinical safety and efficacy of an anti-HIV-1 lentiviral vector containing a short hairpin RNA to CCR5 and the C46 fusion inhibitor. Mol Ther Methods Clin Dev. 2014; 1:11.
211. Tebas P, Stein D, Tang WW, et al. Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N Engl J Med. 2014; 370(10):901-910.
212. Mylvaganam GH, Silvestri G, Amara RR. HIV therapeutic vaccines: moving towards a functional cure. Curr Opin Immunol. 2015; 35:1-8.